Trial · NCT03241342

Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

NCT03241342, Phase 2, Completed, GTx; results first posted 2020-11-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence. Trials, record NCT03241342. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03241342

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence
NCT number: NCT03241342
Status: Completed
Phases: Phase 2
Enrollment: 491 participants, actual
Lead sponsor: GTx
Conditions: Stress Urinary Incontinence
Interventions: GTx 024, Placebo
First posted: 2017-08-07
Last updated: 2021-03-24
Results first posted: 2020-11-12

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12	12 Weeks	Mean number of subject-reported stress incontinence episodes per day through a responder analysis, where a responder is defined as having a ≥ 50% reduction at the end of treatment (Week 12) compared to baseline in the number of stress incontinence episodes

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12	12 Weeks	full analysis set	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12	1 mg GTx-024	94	Participants
Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12	3 mg GTx-024	96	Participants
Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12	Matching Placebo	87	Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	1 mg GTx-024	163
Overall Study	STARTED	3 mg GTx-024	163
Overall Study	STARTED	Matching Placebo	165
Overall Study	COMPLETED	1 mg GTx-024	141
Overall Study	COMPLETED	3 mg GTx-024	132
Overall Study	COMPLETED	Matching Placebo	138
Overall Study	NOT COMPLETED	1 mg GTx-024	22
Overall Study	NOT COMPLETED	3 mg GTx-024	31
Overall Study	NOT COMPLETED	Matching Placebo	27

Source ClinicalTrials.gov

Adverse events756

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	anemia	Blood and lymphatic system disorders	1 mg GTx-024	0	163
other	anemia	Blood and lymphatic system disorders	3 mg GTx-024	1	163
other	anemia	Blood and lymphatic system disorders	Matching Placebo	0	165
other	lymphadenopathy	Blood and lymphatic system disorders	1 mg GTx-024	0	163
other	lymphadenopathy	Blood and lymphatic system disorders	3 mg GTx-024	0	163
other	lymphadenopathy	Blood and lymphatic system disorders	Matching Placebo	1	165
other	polycythaemia	Blood and lymphatic system disorders	1 mg GTx-024	1	163
other	polycythaemia	Blood and lymphatic system disorders	3 mg GTx-024	0	163
other	polycythaemia	Blood and lymphatic system disorders	Matching Placebo	0	165
other	thrombocytosis	Blood and lymphatic system disorders	1 mg GTx-024	1	163

1 to 10 of 756Source ClinicalTrials.gov

See all 756 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	1 mg GTx-024	0	163
Total, all-cause mortality	3 mg GTx-024	0	163
Total, all-cause mortality	Matching Placebo	0	165
Total, other adverse events	1 mg GTx-024	105	163
Total, other adverse events	3 mg GTx-024	104	163
Total, other adverse events	Matching Placebo	96	165
Total, serious adverse events	1 mg GTx-024	3	163
Total, serious adverse events	3 mg GTx-024	2	163
Total, serious adverse events	Matching Placebo	4	165

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03241342

GET https://conductscience.org/api/trials/v1/NCT03241342/events?page=2

API reference For AI assistants